Low Doses of Simvastatin Therapy Ameliorate Cardiac Inflammatory Remodeling in *Trypanosoma cruzi*-Infected Dogs

Lilian Melo, Ivo Santana Caldas, Máfia Araújo Azevedo, Karolina Ribeiro Gonçalves, Alvaro Fernando da Silva do Nascimento, Vivian Paulino Figueiredo, Lívia de Figueiredo Diniz, Wanderson Geraldo de Lima, Rosália Moraes Torres, Maria Terezinha Bahia, and André Talvani*

Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil; Departamento de Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil; Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Abstract. Chagas cardiomyopathy remodeling is based on the presence of *Trypanosoma cruzi* in heart tissue and on the complex inflammatory response leading to a myocardium fibrosis and alterations in conductive and functional heart parameters. This study aims to evaluate Simvastatin on the inflammatory response and heart functionality using dogs infected with Y strain of *T. cruzi*. Animals were treated daily with Simvastatin (20 mg) for 6 months and submitted to clinical and immunopathological evaluations. Simvastatin reduced heart expression and serum levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) but not interleukin-10 (IL-10), possibly favoring blood parasitism but reducing inflammation and fibrosis in the left ventricle and right atrium. Simvastatin also ameliorated ejection fraction, diastolic diameter, and mass index of the left ventricle 6 months after infection. This study suggests that more investigation should be performed on the use of statins as a prophylactic therapy against cardiac remodeling because of their effects on modifying immune response and benefiting functional parameters in dogs with *T. cruzi*-induced ventricular dysfunctions.

INTRODUCTION

Chagas cardiomyopathy (CC) is a progressive inflammatory disease caused by the hemoflagellate parasite *Trypanosoma cruzi* that has caused around 2 million infected individuals in the Americas1 and been considered the most common form of non-ischemic cardiomyopathy worldwide.2 CC is initially marked by the presence of an inflammatory infiltration leading, in some years, to conductive and functional heart alterations.3 It is known that parasites per se or antigenic proteins are essential conditions to trigger and maintain the inflammatory response during CC.4-5 Pro-inflammatory cytokines interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) play a major role controlling tissue parasitism during *T. cruzi* infection, whereas regulatory cytokine interleukin-10 (IL-10) seems to moderate this response, suggesting a protective state to the infected host.6-8 Unfortunately, there is still no available pharmacologic therapy capable of eliminating parasites in the chronic phase of Chagas disease.9 In addition, because of its progressive chronic characteristic, the prognosis of CC is still poor and uncertain. Common and new therapies proposed in clinical treatment of CC aim to (1) maintain or recover the cardiac functions (e.g., β-blockers, angiotensin converting enzyme inhibitors, or digitalis) or (2) act on the genesis of inflammatory response and cardiac remodeling, because this remodeling may continue worsening clinical symptoms in CC.5

Experimental and clinical studies have indicated that 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly referred to as statins, present cardiovascular protective properties that complement their lipid-lowering effects.10-11 Statins have also been shown to improve endothelial function, and mobilize bone marrow-derived stem cells.12-14 Evidence from several large clinical trials has shown that statins reduce morbidity and mortality in patients with distinct cardiovascular diseases, contributing to the improvement of left ventricular function and the prevention or attenuation of progressive left ventricular remodeling in heart failure.15,16

Taking advantage of the great clinical and pathologic similarity existing between human and dogs infected with *T. cruzi*, this study was designed to determine whether Simvastatin reduces inflammatory response in *T. cruzi*-infected mongrel dogs and protects the heart against CC remodeling during acute and recent chronic phases of Chagas disease.

MATERIAL AND METHODS

Parasites. Blood trypomastigote forms of *T. cruzi* Y strain (described as *T. cruzi* II) were maintained through successive passages in Swiss mice at the Laboratory of Chagas disease, Universidade Federal de Ouro Preto (UFOP), Minas Gerais State, Brazil and later, were used in this study. We have previously shown that this strain presents distinct patterns of virulence and pathogenicity in the canine model of heart disease.17

Experimental animals and infection. Fifteen (male and female) 4-month-old mongrel dogs from the Animal Facility at the UFOP were used in this study as mammalian hosts. The investigation conforms to the guidelines issued by the Brazilian College of Animal Experimentation (COBEA), and also, it was approved by the Ethnic Committee in Animal Research (CEUA) at UFOP (number 2009/28). Animals were fed with commercial dog food and water ad libitum. Before this study, animals were dewormed and vaccinated against several infectious diseases. Ten dogs were inoculated with $2.0 \times 10^8$ bloodstream trypomastigotes (Y strain of *T. cruzi*) per 1 kg of body weight. The parasitemia of these animals was examined from the tenth day of infection and until the parasites were no longer detectable in fresh blood collected from the marginal ear vein. In parallel, five non-infected dogs were used as negative controls.
Animals were divided in three distinct groups: (1) five *T. cruzi*-infected dogs, (2) five *T. cruzi*-infected dogs treated daily with Simvastatin (20 mg), and (3) five non-infected dogs as a control group. One tablet of Simvastatin was placed on the oropharyngeal cavity, and the dog was observed for 10 minutes to avoid it spitting the drug. This therapy was initiated at the first day of *T. cruzi* inoculation, and it was continued for 6 months of infection, ending at the time of euthanasia of these animals.

**Measurement of pro- and regulatory cytokines in serum.** For the detection of TNF-α, IFN-γ, and IL-10 (R&D systems, Minneapolis, MN) in plasma, 10-mL blood samples were collected monthly from each dog, and serum was stored at −80°C. Samples were defrosted and immediately processed using kits from R&D systems for dog cytokines. Briefly, flat-bottomed 96-well microtiter plates (Nunc) were coated with 100 μL/well of the appropriate monoclonal antibodies for 18 hours at 4°C and then washed with phosphate-buffered saline (PBS) buffer (pH 7.4) containing 0.05% Tween 20 (wash buffer). Non-specific binding sites were blocked with 200 μL/well of 1% bovine serum albumin (BSA) in PBS (blocking buffer). Plates were rinsed with wash buffer, and samples were added (100 μL/well) followed by incubation for 18 hours at 4°C. Plates were then washed, and 100 μL/well of the appropriate biotinylated detection antibodies diluted in blocking buffer containing 0.05% Tween 20 were added for 1 hour at room temperature. Plates were washed, streptavidin-horseradish peroxidase was added, and plates were incubated for 30 minutes at room temperature. Finally, plates were washed, and 100 μL/well of the chromogen substrate o-phenylenediamine (OPD; Sigma), diluted in 0.03 M citrate buffer containing 0.02% 30v/v H2O2, were added; after 30 minutes of a dark incubation at room temperature, the reaction was stopped by 50 μL/well of 1 M H2SO4 solution. Plates were read at 492 nm in a spectrophotometer (Emax; Molecular Devices). All samples were assayed in duplicate.

**Semiquantitative analysis of IFN-γ and IL-10 expression in heart tissue.** RNA was isolated from the right atrium of dogs by acidic guanidinium thiocyanate–phenol–chloroform extraction. Polymerase chain reaction (PCR) conditions were as follows: 94°C for 5 minutes, 94°C for 1 minute, 57°C for 1 minute, 72°C for 2 minutes (three steps, *n* cycles), 57°C for 1 minute, and 72°C for 6 minutes (final extension). Primers (sense and antisense) sequenced from 5′ to 3′ are followed by the number of cycles and the expected product size of PCR according our previous standardization (shown in parentheses). IFN-γ: CGGCCTAACCCTCTGGAAACGC, CCT C TTC TACTCGTGCGTCGTCGTGCTG (38, 380 bp); IL-10: AGCA GCC TACTTGAGGGAGCA, GATGTCTGGGTGGTGTGTTCT (40, 249 bp). Hypoxanthine phosphoribosyltransferase (HPRT): AAGCCTTGGTGTGGAAGAGGA, CAATGGAATCTCCAGATGT (28, 219 bp; all primers from Dialab, Brazil). PCR products and molecular weight markers were run on 6% polycrylamide gel and stained with silver nitrate. PCR products on silver-stained gels were quantified with a densitometer using a Quantity One program (The Discovery Series 1998; Biorad Laboratories). The densitometry values for each cytokine were divided by the average value for the HPRT for the same sample.

**Doppler echocardiography.** Left ventricular parameters of heart dysfunction were evaluated at day 0 (before *T. cruzi* infection) and 3 and 6 months after infection, equivalent to acute and recent chronic phases of Chagas disease. Dogs were anesthetized by injection of sodic pentobarbital (Thiopentax, Cristália, SP, Brazil) at 0.5 mL/kg of body weight (0.03 g/mL in 0.89% saline solution), and all studies were performed on an Acuson Cypress Portable Ultrasound Machine (Siemens) and analyzed by an echocardiologist blinded to all clinical forms of the animals. More than 300 different parameters were collected and analyzed, but in this study, only left ventricle ejection fraction, left ventricle diastolic diameter, and mass index were shown. Animals were followed by researchers during the anesthesia recuperation, with no death registered during or after echocardiography evaluation.

**Morphometric and histopathology analysis.** Animals were euthanized 6 months after the infection by an overdose of sodic pentobarbital (Thiopentax, Cristália, S, Brazil). Fragments of approximately 1.0 × 1.0 × 0.2 cm from the middle of the right atrial and left ventricle walls of each dog were taken for morphometric and histopathology analyses. Tissue fragments were fixed in 10% buffered formalin solution, dehydrated, cleared, and embedded in paraffin. Blocks were cut into 4-mm-thick sections and stained by hematoxylin and eosin (H&E) for inflammation assessment or Masson’s trichromic for fibrosis quantitative evaluation. Twenty fields from each H&E- or Masson’s trichromic-stained section were randomly chosen at 28, 219 bp (all primers from Dialab, Brazil). PCR products were added (1% bovine serum albumin (BSA) in PBS (blocking buffer) containing 0.05% Tween 20 were added for 1 hour at room temperature. Plates were washed, streptavidin-conjugated horseradish peroxidase was added, and plates were incubated for 30 minutes at room temperature. Finally, plates were washed, and 100 μL/well of the chromogen substrate o-phenylenediamine (OPD; Sigma), diluted in 0.03 M citrate buffer containing 0.02% 30v/v H2O2, were added; after 30 minutes of a dark incubation at room temperature, the reaction was stopped by 50 μL/well of 1 M H2SO4 solution. Plates were read at 492 nm in a spectrophotometer (Emax; Molecular Devices). All samples were assayed in duplicate.

**Statistical analysis.** The results of serological assays, cytokine expression, histological data, and echocardiography parameters were analyzed by non-parametric Newman-Keuls Multiple Comparison and Tukey tests. Difference was considered significant if *P* was equal to or less than 0.05.

**RESULTS**

Simvastatin alters pattern of circulating parasites. Low doses of statins did not alter circulating lipid levels in infected dogs treated with Simvastatin (*N* = 5) during 0.3, and 6 months of *T. cruzi* infection, respectively, in mean ± standard error of the mean (SEM): (1) infected dogs (184.2 ± 19.79, 208.5 ± 31.93, and 190.9 ± 8.02 μg/dL) and (2) infected dogs plus Simvastatin (165.0 ± 10.71, 205.2 ± 8.98, and 180.3 ± 2.27 mg/dL). However, in terms of infection, a significantly higher parasitemia was observed between the days 11 and 14 after infection in animals treated with Simvastatin (Figure 1).
Low doses of Simvastatin alter pro-inflammatory cytokines in acute and chronic phases of Chagas disease. Initial *T. cruzi* replication is partially controlled by pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-12, and oxygen derivatives (e.g., nitric oxide). Low doses of Simvastatin (20 mg/day) were capable of reducing serum levels of both pro-inflammatory TNF-α (Figure 2A) and IFN-γ (Figure 2B) around the first 2 months of infection but did not interfere in the regulatory cytokine IL-10 (Figure 2C). However, long-term therapy with this statin had an inversion of this systemic pattern of cytokines during the recent chronic phase of infection, showing a significant increase of IL-10 circulating levels but not the pro-inflammatory cytokines in the infected dogs treated with Simvastatin.

During this recent chronic phase, animals were euthanized, and the expression of two representative Th1 (IFN-γ) and Th2 (IL-10) cytokines were measured in the heart tissue. Reinforced by our systemic data, messenger RNA (mRNA) expression of IL-10 (Figure 3B) was increased in those animals treated with Simvastatin, whereas the majority of IFN-γ (Figure 3A) was observed only in those infected and untreated dogs.

**Histopathological findings after treatment with Simvastatin.** In this work, we did not observe evidence of amastigote nests in heart tissue of all evaluated groups. Comparisons among cellular nuclei from heart tissue derived from *T. cruzi*-infected dogs submitted to Simvastatin therapy or no therapy were made in the right atrium and left ventricle after 6 months of evaluation. Scattered infiltrating cells were observed in both treated and untreated infected dogs in the right atrium (Figure 4A and B) and left ventricle (Figure 5A and B), with no detectable abnormalities found in the vascular wall. A full analysis of this inflammatory pattern can be visualized in Figure 4E for the right atrium and in Figure 5E for the left ventricle, and regarding the volumetric proportions of the inflammatory process, the mean values were significantly higher in *T. cruzi*-induced chronic myositis than in those non-infected control animals.

Interestingly, despite the capacity of Simvastatin to reduce the inflammatory infiltration (Figures 4E and 5E) in heart tissue, there were no differences in fibrosis in the right atrium (Figure 4C and D) and left ventricle (Figure 5C and D) between untreated infected dogs and those receiving 20 mg Simvastatin. The mean values of this quantification of collagen area in heart tissues are better observed in the right atrium in Figure 4F and in the left ventricle in Figure 5F.
Simvastatin preserves functional parameters in chronic Chagas cardiomyopathy. Daily low doses of Simvastatin (20 mg) did not have significant effects on cardiac parameters at the end of the acute phase (3 months) of canine Chagas disease. However, in the recent chronic phase (6 months), it was observed to have a protective effect on the left ventricle ejection fraction (Figure 6A), diastolic end diameter (Figure 6B), and mass index (Figure 6C) in all infected dogs treated with Simvastatin. No significant differences were observed among non-infected animals during 3 and 6 months of evaluation for those evaluated parameters (data not shown).

DISCUSSION

Cardiac remodeling is best described as a process defined by structural changes in one or more cardiac chambers, particularly the ventricles. During CC, the cardiac remodeling is a pivotal process to define the progression to the mild or severe clinical forms of the disease. Underlying mechanisms are many fold; myocardial stretch and neurohormonal and cytokine activation are crucial processes in response to *T. cruzi* infection.425 Because heart injuries in CC seem to be partially defined by a common set of inflammatory responses, therapies aimed at counteracting these mechanisms might prove successful in attenuating or even preventing cardiac remodeling in the human or experimental model of Chagas disease. In this way, angiotensin converting enzyme inhibition and β-blockers, prescribed routinely to Chagasic patients, has already proven to be effective in reducing the occurrence of adverse events in inflammatory-dependent CC in human and experimental models.21-26

Data from this present study show that therapy with low doses of Simvastatin, the inhibitor of HMG-CoA reductase, significantly retards the progression of CC in dogs, which is the well-defined model to study immunological and clinical responses of Chagas disease because of its similarity with the human data.17 The key finding here is that Simvastatin administered to combat *T. cruzi* infection can modulate the immune response in hosts during initial steps of acute phase and persist during the chronic phase. Many of these cholesterol-independent effects reflect the ability of statins to affect on this anti-inflammatory process (e.g., reducing activation of the transcription factor nuclear factor κB, modulating nitric oxide, endothelin-1, and pro-inflammatory cytokines, and blocking the synthesis of important isoprenoid intermediates).13,14
By inhibiting l-mevalonic acid synthesis, statins prevent the synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesylpyrophosphate and geranylgeranylpyrophosphate. In trypanosomatids, the importance of isoprenoids for cell viability and proliferation has previously been proven, and the combination of inhibitors that act at different points of the pathway seems to be useful against \( T. cruzi \). However, we do not observe interference of low doses of Simvastatin on trypomastigote surviving during the acute phase. Conversely, there was an increased level of circulating parasites during 2 weeks post-infection, culminating in a higher parasitemia peak observed in those dogs treated with Simvastatin. These data could be partially explained by the gap failure in the inflammatory response. Pro-inflammatory cytokines (e.g., IFN-\( \gamma \) and TNF-\( \alpha \)) have been shown to be essential to activate and drive macrophages in controlling parasites growth, dependently or not of nitric oxide. In addition to these activated macrophages, there is a clear role for CD4 and CD8 T cells in the control of the acute phase and also, in the magnitude of inflammatory response through chemokine leukocyte recruitment \textit{in vivo} or \textit{in vitro}. In accordance with these points, Simvastatin reduced serum levels of TNF-\( \alpha \) and IFN-\( \gamma \) in all infected animals, and possibly, this modulation interfered directly with the control of circulating parasites during the acute phase. This pattern of pro-inflammatory cytokines was maintained by Simvastatin during the initial acute phase but was changed later by an increasing production of IL-10, not TNF-\( \alpha \) and IFN-\( \gamma \) coinciding with the beginning of the chronic phase. The regulatory cytokine IL-10 might interfere with the ability of the mammalian host to deal with the infection, especially controlling the Th1-predominant immune response against \( T. cruzi \) and possibly, preventing unwanted excessive heart inflammation.

This Th polarization was also observed in the heart tissue (low mRNA expression for IFN-\( \gamma \) and high for IL-10) from those animals treated for 6 months with statins. Taking the similarity of dog models to human immunogenesis of Chagas disease, our data might suggest a protective condition against the inflammatory process induced by Simvastatin and consequently, for CC remodeling. Gomes and others\(^{32,33}\) show the importance of Th cytokine polarization to the prognosis of human CC. Their data, supported by others, can be explained by the abilities of pro-inflammatory cytokines (e.g., IFN-\( \gamma \)) to modulate chemokine production, which is responsible for driving leukocyte recruitment to eliminate antigenic stimuli in the inflammatory site. This inflammatory response, considered necessary for parasite control, can become unwanted,
Simvastatin therapy significantly reduces the inflammatory infiltration in dogs infected with T. cruzi (white box) and infected dogs treated with Simvastatin (gray box). The non-infected group maintained an unaltered pattern of ventricular function for 3 and 6 months. Letters indicate significant differences, and identical letters indicate similar values among infected groups untreated and treated with Simvastatin.

REFERENCES


6. Abrahamsohn IA, Coffman RL. 1996. Trypanosoma cruzi: IL-10, TNF, IFN-gamma and IL-12 regulate innate and acquired immunity to infection. Exp Parasitol 84: 231–244.

Simvastatin ameliorates Chagas heart disease


